In that study, first-degree male relatives of breast cancer patients carrying protein-truncating BRCA2 mutations had a RR of 4.8 (95%CI 3.3–6.3) for prostate cancer (Tulinius et al, 2002). This evidence concerns the gene BRCA2 and prostate carcinoma.